FDA staff unsure about new use for Amgen's Xgeva
February 6, 2012 — WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.
UK says home-grown cancer pill too costly to use
February 2, 2012 — LONDON (Reuters) - Britain's health cost watchdog NICE sparked a major row on Thursday by snubbing a pricey new prostate cancer pill discovered at the country's top cancer research center, a decision critics said was bad for patients and research.
Seed therapy for prostate cancer may zap fertility
February 1, 2012 — NEW YORK (Reuters Health) - Radioactive "seeds" that are sometimes used to treat early prostate cancer may do widespread damage to the DNA in a man's sperm, a small study finds.
Select news items provided by Reuters Health